drugset / Trial / NCT04622761
Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome
Phase 2
Unknown
120 enrolled
The Clatterbridge Cancer Centre NHS Foundation Trust
University of Liverpool · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is evaluating the efficacy of cabazitaxel and hormonal treatment as neoadjuvant treatment for patients with clinically operable disease suitable for surgery, and a high risk of relapse after surgery
Timeline
- Start
- 2021-01-15
- Primary completion
- 2025-11-02
- Completion
- 2026-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabazitaxel | Other / unclassified | 25 mg/m2 | Intravenous |